MYDA Advisors LLC Acquires New Holdings in Becton, Dickinson and Company $BDX

Key Points

• MYDA Advisors LLC disclosed a new position in Becton, Dickinson and Company, buying 10,000 shares valued at about $1.94 million in the fourth quarter.
• Other institutional investors also increased or initiated stakes in BDX, and institutions now own 86.97% of the company’s shares.
• Analysts remain mixed on BDX: the stock carries a Hold consensus with an average price target of $182.73, while recent reports included both raised targets and rating downgrades.

MYDA Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,000 shares of the medical instruments supplier's stock, valued at approximately $1,941,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company during the third quarter valued at approximately $25,000. Steph & Co. raised its position in Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 65 shares in the last quarter. Accredited Wealth Management LLC raised its position in Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 70 shares in the last quarter. WPG Advisers LLC raised its position in Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 61 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $32,000. Institutional investors own 86.97% of the company's stock.

Analysts Set New Price Targets

BDX has been the topic of several recent research reports. Barclays raised their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an "overweight" rating in a research report on Monday, May 11th. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Weiss Ratings lowered shares of Becton, Dickinson and Company from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Monday, May 11th. The Goldman Sachs Group dropped their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 27th. Finally, BofA dropped their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $182.73.

Becton, Dickinson and Company Trading Down 0.1%

NYSE:BDX opened at $146.13 on Monday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The firm has a market cap of $40.27 billion, a price-to-earnings ratio of 37.00, a P/E/G ratio of 10.35 and a beta of 0.22. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The company's 50 day moving average is $150.00 and its 200-day moving average is $173.93.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter last year, the firm posted $3.35 earnings per share. The company's quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 106.33%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the firm's stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $151.48, for a total value of $166,628.00. Following the sale, the executive vice president owned 14,272 shares in the company, valued at approximately $2,161,922.56. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 4,013 shares of company stock worth $593,434. 0.40% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.